Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
The U.S. Food and Drug Administration (FDA) approved Janssen‘s new formulation of daratumumab — a subcutaneous or under-the-skin injection treatment called Darzalex Faspro (daratumumab and hyaluronidase) — as a faster and easier ... Read more
Actemra (tocilizumab), a medicine approved for certain types of arthritis, may be effective in treating severe infections with the new coronavirus in people with multiple myeloma or other blood disorders, ... Read more
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people ... Read more
I-Mab Biopharma has dosed the first patient in mainland China in its ongoing, pivotal Phase 2 trial assessing MorphoSys‘s investigational antibody therapy MOR202 (TJ202) as treatment for people with relapsed ... Read more
Treatment with Regeneron Pharmaceuticals‘ investigational therapy REGN5458 was well tolerated and significantly lowered the tumor burden in more than half of heavily treated multiple myeloma patients in a Phase 1 ... Read more
Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an optimal blood level of the medicine for ... Read more
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new formulation ... Read more
Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients given a placebo, a Phase 3 clinical ... Read more
The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days. The approval ... Read more
Janssen Biotech has asked that the U.S. Food and Drug Administration to expand the label for Darzalex (daratumumab) to include its use, in combination with standard Revlimid (lenalidomide) and dexamethasone, as a first-line treatment ... Read more